# Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients

> **NCT00133224** · PHASE3 · TERMINATED · sponsor: **Cell Genesys** · enrollment: 408 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** Immunotherapy allogeneic GM-CSF secreting cellular vaccine
- **DRUG:** Chemotherapy (docetaxel and prednisone)

## Key facts

- **NCT ID:** NCT00133224
- **Lead sponsor:** Cell Genesys
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-07
- **Primary completion:** 2008-08
- **Final completion:** 2009-06
- **Target enrollment:** 408 (ACTUAL)
- **Why stopped:** Accrual and treatment with CG1940/CG8711 stopped due to IDMC recommendation.
- **Last updated:** 2008-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00133224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00133224, "Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00133224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*